About the project
The DRKS is funded by the Federal Ministry of Education and Research (BMBF) and implemented at the Center for Medical Biometry and Medical Informatics at the University Medical Center Freiburg as a common project of the Clinical Trial Unit of the University Medical Center Freiburg and the German Cochrane Center.
The DRKS was implemented and is further developed in collaboration with the WHO especially with the ICTRP. It is an approved WHO Primary Register since October 2008 and thus meets the requirements of the ICMJE, whose members decided in September 2004 already that the prospective registration of clinical trials was a necessary requirement for later publications in the leading medical journals. Find out more under "International Network".
Various different user groups will have a potential benefit from the German Clinical Trials Register.
- Self help groups
- Ethics committees
- Pharmaceutical industry
- Research funding institutions
- Non-physician health care professions
Patients and their physicians will have a central portal for information on all trials and especially on ongoing trials, suitable for participation. Moreover, investigators can use the DRKS to provide information on their trials, thus facilitating recruitment. The DRKS also imports trials from other registers to avoid duplication of work and for a full picture of the study situation in Germany. Self help groups get an independent overview on ongoing and new trials which can be used to inform their members.
Clinical research usually takes place in networks. Trial registers can function both as platforms for new cooperation of different research groups in Germany and beyond and as an instrument to display this networked research. The review process which is conducted on different levels and in different contexts (e.g. ethics committees, authorities) can be supported by independent and extensive information on existing evidence and on planned, ongoing and finished clinical trials. Unnecessary duplication of research can thus be avoided.
The German Clinical Trials Register will, for the first time, allow a comprehensive analysis of the clinical research situation in Germany. Neglected clinical research areas as well as competence centers of expertise in clinical research or specific diseases can be identified. These figures may serve as a valid basis for the funding and performing of clinical research in Germany and also for the pharmaceutical industry to get an impression on the expertise and the scientific focus of a business location.